Recombinant Human SUMO1 aa 1-97
- Known as:
- Recombinant Human SUMO1 aa 1-97
- Catalog number:
- CRS138C
- Product Quantity:
- 1.0 mg
- Category:
- -
- Supplier:
- Cell Sciences
- Gene target:
- Recombinant Human SUMO1 1-97
Related genes to: Recombinant Human SUMO1 aa 1-97
- Gene:
- AGAP11 NIH gene
- Name:
- ArfGAP with GTPase domain, ankyrin repeat and PH domain 11
- Previous symbol:
- -
- Synonyms:
- KIAA1975
- Chromosome:
- 10q23.2
- Locus Type:
- unknown
- Date approved:
- 2008-09-22
- Date modifiied:
- 2015-11-17
- Gene:
- ALG14 NIH gene
- Name:
- ALG14 UDP-N-acetylglucosaminyltransferase subunit
- Previous symbol:
- -
- Synonyms:
- MGC19780
- Chromosome:
- 1p21.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-08-09
- Date modifiied:
- 2019-01-18
- Gene:
- ANKHD1 NIH gene
- Name:
- ankyrin repeat and KH domain containing 1
- Previous symbol:
- -
- Synonyms:
- MASK, FLJ20288, FLJ11979, FLJ10042, FLJ14127, KIAA1085, MASK1
- Chromosome:
- 5q31.3
- Locus Type:
- gene with protein product
- Date approved:
- 2004-04-16
- Date modifiied:
- 2015-03-24
- Gene:
- ANKS3 NIH gene
- Name:
- ankyrin repeat and sterile alpha motif domain containing 3
- Previous symbol:
- -
- Synonyms:
- KIAA1977, FLJ32345, FLJ32767
- Chromosome:
- 16p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2006-02-17
- Date modifiied:
- 2014-11-19
- Gene:
- BUD23 NIH gene
- Name:
- BUD23 rRNA methyltransferase and ribosome maturation factor
- Previous symbol:
- WBSCR22
- Synonyms:
- MGC19709, MGC2022, MGC5140, PP3381, WBMT, MERM1
- Chromosome:
- 7q11.23
- Locus Type:
- gene with protein product
- Date approved:
- 2001-08-24
- Date modifiied:
- 2019-03-11
Related products to: Recombinant Human SUMO1 aa 1-97
Related articles to: Recombinant Human SUMO1 aa 1-97
- Hypoxia-ischaemia and reperfusion (HI/R) damage is a result stemming from any event that interrupts the brain's blood supply, such as the occlusion of a blood vessel. In neurons, the molecular mechanisms involved in the HI/R cascade are diverse in nature, ranging from proteomic, genomic, and transcriptomic alterations in the cells. Many of these changes are governed by post-translational modifications such as SUMOylation, which can quickly and reversibly alter the fate of key proteins. This review summarises current evidence regarding the role of SUMOylation in key molecular pathways in major in vivo and in vitro models of cerebral HI/R. Our review reinforces the concept of SUMOylation being a dynamic and time-dependent process that functions as a rapid molecular switch, affecting major pathways across different cell types and cellular compartments. Moreover, the context-dependent pathological and neuroprotective action of SUMOylation in different pathways involved in HI/R is explored. It sheds light on a novel notion placing aberrant SUMO-1 conjugation as the main culprit in reperfusion damage, whereas SUMO-2/3 principally serves as a compensatory mechanism during ischaemia to prevent damage. Nevertheless, it also highlights important gaps in the current scientific evidence regarding the role of SUMO, underscoring the need for further investigation. - Source: PubMed
Gissoni João MCampos Kiara FVieira Helena L ANetto Carlos AlexandreDurán-Carabali Luz ElenaCimarosti Helena I - Lung cancer remains a leading cause of cancer-related death, highlighting the urgent need for new treatment strategies. SUMOylation, a post-translational modification that regulates DNA repair, replication, and cell cycle progression, is often increased in cancers and is a promising therapeutic target. Previously, we identified alternative splicing events affecting the SUMO transcripts, resulting in variant mRNAs coding for both non-conjugatable (SUMO1α and SUMO2α) and conjugatable (SUMO3α) isoforms-potentially helping to regulate overall cellular SUMOylation. In this study, we investigated whether increasing the levels of the transcripts coding for the non-conjugatable isoforms could decrease SUMOylation and improve chemotherapy efficacy in non-small cell lung cancer (NSCLC). To test this, we designed two sets of exon-skipping morpholinos called SUM2IN and SUMO1IN, targeting the pre-mRNAs of SUMO2 and SUMO1, respectively, and tested them in A549 and HCC827 cell lines. While treatment with SUM2IN significantly increased SUMO2α mRNA and reduced overall SUMO1 and SUMO2 conjugation in all tested cell lines, SUM1IN affected the proportion of SUMO1 mRNA variants and overall SUMO conjugation in a cell-type-specific manner. Still, both SUM2IN and SUM1IN altered cell cycle progression, decreased cell growth, and enhanced the cytotoxic effects of cisplatin and etoposide in A549 and HCC827 cells, while having a notably smaller impact on these parameters in the non-malignant lung fibroblast cell line HEL-299. Therefore, SUM2IN and SUM1IN display chemosensitizing activity against NSCLC and provide a strong foundation for developing SUMO-targeted chemosensitizers for NSCLC and other aggressive human cancers. - Source: PubMed
Publication date: 2026/05/05
Garcia-Morin AndreaOrozco-Sepulveda RebecaJuarez-Vargas YeseniaBanuelos ClaudiaGutierrez-Zubiate IsabelRosas-Acosta German - Acute severe ulcerative colitis (ASUC) now imposes an increasing global burden, yet lacks broadly effective therapeutic options. While organoid transplantation represents a promising approach for intestinal injuries, its efficacy for ASUC treatment remains suboptimal. Here, we elucidate the intrinsic mechanism of RIPK1 involvement in necroptosis initiation, and further develop an organoid-based dual-axis therapeutic paradigm for ASUC. We identified that RIPK1 undergoes PIAS1-catalyzed SUMO1 modification at lysine 305, which promotes its compartmentalization within phase-separated structures, thereby serving as nucleation platforms for accelerating RIPK3 amyloid fibril assembly. Interfering with phase separation of RIPK1 suppresses necroptosis in intestinal cells and colonic organoids in vitro, as well as alleviates intestinal injury and reduces mortality in vivo. Notably, while colonic organoid transplantation showed limited therapeutic efficacy in ASUC, a synergistic therapy combining necroptosis blockade and organoid transplantation effectively reduced inflammatory damage and enhanced epithelial regeneration by reprogramming the intestinal microenvironment. These findings suggest that the SUMO1-RIPK1 axis functions as a druggable checkpoint governing necroptotic cell fate and presents a clinically actionable strategy to potentiate regenerative medicine paradigms in ASUC pathogenesis. - Source: PubMed
Publication date: 2026/05/13
Deng QifengLiu JiruShen JianYang SidiZhao XinWang WenruLu JianruLiu LihongZhou LiangCai SihuiZeng LinsenZhou XiaoqianCui Jun - Neurodegenerative diseases (NDDs) represent a growing global health burden, particularly in aging populations. These disorders primarily affect neurons and are characterized by progressive neuronal dysfunction and loss within specific regions of the central nervous system. Major NDDs include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and stroke. Although each disorder exhibits distinct genetic backgrounds and pathological protein aggregates, they share common pathogenic mechanisms, including chronic neuroinflammation, impaired autophagy and mitophagy, disrupted proteostasis, telomere instability, and epigenetic alterations. A hallmark feature across NDDs is the accumulation of misfolded proteins, leading to synaptic dysfunction and neuronal degeneration. Small ubiquitin-like modifiers (SUMOs) are a family of ∼100 amino acid proteins, including SUMO1 and the closely related SUMO2/3 isoforms. SUMOylation is a dynamic posttranslational modification that regulates protein function through the covalent attachment or removal of SUMO moieties. This reversible process is mediated by SUMO-specific E1 activating, E2 conjugating, and E3 ligating enzymes and is counterbalanced by SUMO/Sentrin-specific proteases. The SUMOylation status of target proteins depends on the tightly controlled balance between conjugation and deconjugation systems. Acting as a molecular switch, SUMOylation modulates diverse cellular processes such as DNA damage repair, RNA metabolism, transcriptional regulation, and protein quality control, all of which are essential for maintaining cellular homeostasis. Accumulating evidence links dysregulated SUMOylation to the pathogenesis of multiple neurological disorders, including polyglutamine and synucleinopathies. SUMOylation influences neuroinflammation, oxidative stress, protein aggregation, neuroangiogenesis, ischemic injury, and demyelination. This review highlights recent advances in understanding the role of SUMOylation in NDDs and explores its potential as a promising therapeutic target. - Source: PubMed
Publication date: 2026/05/07
Oriquat GhalebJasim Ihsan KGajjar Tushar BHanumanthayya MalathiAbdulhameed Ahmad IsraaSingh GunjanMaharana LaxmidharBainsal Neeraj - Simian immunodeficiency viruses (SIVs) have crossed from apes to humans at least four times, but only one event gave rise to the AIDS pandemic. The host barriers that pandemic HIV-1 group M () strains overcame to spread efficiently in humans remain poorly understood. To identify such barriers, we performed CRISPR-Cas9 screens driven by the replication efficiency of SIVcpz, the chimpanzee precursor of HIV-1. Guide RNA libraries targeting more than 500 human genes encoding potential antiviral factors were inserted into the replication-competent SIVcpz MB897 molecular clone, which is phylogenetically closely related to HIV-1 group M strains. Propagation in Cas9-expressing human SupT1 T cells significantly enriched for sgRNAs targeting and . These hits only partially overlapped with those identified in analogous HIV-1-based screens, indicating virus-specific restriction profiles. Functional analyses confirmed that IFITM2 (interferon-induced transmembrane protein 2), PCED1B (PC-esterase domain-containing protein 1B), MEFV (Mediterranean fever protein, pyrin/TRIM20), and AXIN1 (Axis inhibition protein 1) restrict replication of the analyzed SIVcpz strains but not HIV-1 group M strains in primary human CD4 T cells. These findings reveal previously unrecognized host factors that limit SIVcpz replication in human cells and highlight barriers that at least some HIV-1 group M strains overcame during adaptation for pandemic spread. - Source: PubMed
Publication date: 2026/05/07
Xie QinyaWang QingxingNoettger SabrinaGosálbez GuillermoBetzler Annika CVolcic MetaKmiec DorotaKrebs StefanGraf AlexanderGülensoy DilaWeidinger GilbertSparrer Konstantin M JKirchhoff Frank